Angiogenic and hypoxia markers in non-small cell lung cancers: evaluation of clinical and prognostic
- Prosjektnummer
- SFP740-08
- Ansvarlig person
- Roy M. Bremnes
- Institusjon
- Universitetssykehuset Nord-Norge HF
- Prosjektkategori
- Flerårig forskningsprosjekt
- Helsekategori
- Cancer and neoplasms
- Forskningsaktivitet
- 1. Underpinning
Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival.
PLoS One 2011;6(8):e23847. Epub 2011 aug 22
PMID: 21887331
Correlation and coexpression of HIFs and NOTCH markers in NSCLC.
Anticancer Res 2011 May;31(5):1603-6.
PMID: 21617216
Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2.
PLoS One 2011;6(5):e19773. Epub 2011 mai 16
PMID: 21603628
Diverging prognostic impacts of hypoxic markers according to NSCLC histology.
Lung Cancer 2011 Jun;72(3):294-302. Epub 2010 nov 13
PMID: 21075472
The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer.
J Thorac Oncol 2011 Apr;6(4):824-33.
PMID: 21173711
Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
J Thorac Oncol 2010 Oct;5(10):1536-43.
PMID: 20802349
Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival.
Cancer 2010 Dec;116(24):5676-85. Epub 2010 aug 24
PMID: 20737536
Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer.
Cancer 2010 Sep;116(18):4318-25.
PMID: 20549821
The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma.
APMIS 2010 May;118(5):371-82.
PMID: 20477813
PhD
- Disputert:
- desember 2011
- Hovedveileder:
- Roy Bremnes
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport, Helse Nord